Allogene Therapeutics, Inc. Common Stock (ALLO) is a publicly traded Healthcare sector company. As of October 26, 2026, ALLO trades at $1.26 with a market cap of $431.86M and a P/E ratio of -1.61. ALLO moved +1.20% today. Year to date, ALLO is -8.76%; over the trailing twelve months it is +3.31%. Its 52-week range spans $0.86 to $4.46. Analyst consensus is strong buy with an average price target of $10.25. Rallies surfaces ALLO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks ALLO insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $1.26 |
| Market Cap | $431.86M |
| P/E Ratio | -1.61 |
| EPS | $-0.87 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.46 |
| 52-Week Low | $0.86 |
| Volume | 1.52M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-190.89M |
| Gross Margin | 0.00% |
7 analysts cover ALLO: 0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.25.